Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

2026-02-21 05:48:20

Biogen (NASDAQ: BIIB) reported stronger-than-expected fourth-quarter earnings and revenues, surpassing analyst consensus. Following these upbeat results, several analysts, including those from Piper Sandler, HC Wainwright & Co., and Wedbush, raised their price targets for the pharmaceutical company. The company also provided an optimistic fiscal 2026 earnings outlook, although it anticipates a slight decline in overall revenue due to expected decreases in Multiple Sclerosis product revenue.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.